Amylin (IAPP), a gluco-modulatory hormone co-expressed with insulin by pancreatic β cells, is downregulated in both T1D and advanced T2D (Abedini et al. 2013), while amylin agonists are considered novel therapeutic agents for treating diabetes (Sonne et al. 2021). Here, IAPP is linked to type 2 diabetes mellitus.